Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: analyses from OPUS-TIMI 16 and TACTICS-TIMI 18.

AIMS To investigate the relationship between diabetes and inflammation and the potentially synergistic relationship between hyperglycaemia and inflammation on clinical outcomes in non ST-elevation ACS. METHODS AND RESULTS The principal analysis was conducted in 2200 patients in OPUS-TIMI 16 with C-reactive protein data available and then validated in the invasive arm of TACTICS-TIMI 18 (n = 929). In addition, two further inflammatory markers [monocyte chemoattractant protein-1 (MCP-1) and von Willebrand factor (vWF)] were assessed in OPUS-TIMI 16. Diabetic patients had higher C-reactive protein and MCP-1 levels vs. non-diabetic patients in OPUS-TIMI 16 (9 vs. 7.8 mg/L, P = 0.002, and 190.6 vs. 170.8 pg/mL, P = 0.04, respectively), higher C-reactive protein levels in TACTICS-TIMI 18 (6.6 vs. 5.2 mg/L, P = 0.0005), and as expected higher glucose levels in both trials. Stratifying by the median C-reactive protein and diabetes in OPUS-TIMI 16, diabetic patients with C-reactive protein greater than or equal to the median were the highest risk group vs. non-diabetic patients with C-reactive protein less than the median (adjusted HR 1.63, 95% CI 1.20-2.23, P = 0.002). Directionally, similar findings were observed for MCP-1 and vWF in OPUS-TIMI 16 and for C-reactive protein in TACTICS-TIMI 18. After adjustment for diabetes, the risk associated with a 1 mmol/L increase in glucose was greater among those with a C-reactive protein greater than or equal to the median (HR 1.07, 95% CI 1.03-1.11) vs. those with a C-reactive protein less than the median (HR 1.02, 95% CI 0.97-1.06). After multivariable adjustment, the synergistic relationship between glucose and C-reactive protein and clinical outcomes remained statistically significant (P = 0.01). A similar pattern was observed in TACTICS-TIMI 18. CONCLUSION Among ACS patients, diabetes was associated with both greater inflammation and higher glucose levels and patients with both hyperglycaemia and inflammation had worse outcomes. Better control of both inflammation and hyperglycaemia should be assessed in future ACS trials as a means to reduce the cardiovascular risk among diabetics.

[1]  E. Braunwald,et al.  Association between blood glucose and long-term mortality in patients with acute coronary syndromes in the OPUS-TIMI 16 trial. , 2006, The American journal of cardiology.

[2]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[3]  R. Giugliano,et al.  U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. , 2005, Journal of the American College of Cardiology.

[4]  R. Heine,et al.  Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus. , 2004, Archives of internal medicine.

[5]  Tzung-Dau Wang,et al.  Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. , 2004, The American journal of cardiology.

[6]  E. Topol,et al.  Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. , 2004, European heart journal.

[7]  S. Jo,et al.  Nitric Oxide Production and Regulation of Endothelial Nitric-oxide Synthase Phosphorylation by Prolonged Treatment with Troglitazone , 2004, Journal of Biological Chemistry.

[8]  P. Libby,et al.  Soluble CD40L: Risk Prediction After Acute Coronary Syndromes , 2003, Circulation.

[9]  Petr Jarolim,et al.  Elevated Plasma Levels of the Atherogenic Mediator Soluble CD40 Ligand in Diabetic Patients: A Novel Target of Thiazolidinediones , 2003, Circulation.

[10]  M. Roden,et al.  Diabetic LDL triggers apoptosis in vascular endothelial cells. , 2003, Diabetes.

[11]  W. Koenig,et al.  Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery Disease , 2003, Circulation.

[12]  S. Verma,et al.  Hyperglycemia potentiates the proatherogenic effects of C-reactive protein: reversal with rosiglitazone. , 2003, Journal of molecular and cellular cardiology.

[13]  E. Antman,et al.  Association Between Plasma Levels of Monocyte Chemoattractant Protein-1 and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndromes , 2003, Circulation.

[14]  S. Devaraj,et al.  C-Reactive Protein Increases Plasminogen Activator Inhibitor-1 Expression and Activity in Human Aortic Endothelial Cells: Implications for the Metabolic Syndrome and Atherothrombosis , 2003, Circulation.

[15]  J. W. Box,et al.  Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb Study , 2000 .

[16]  A. Hata,et al.  Advanced glycation end products-induced gene expression of scavenger receptors in cultured human monocyte-derived macrophages. , 2000, Biochemical and biophysical research communications.

[17]  R. Cannon.  Cardiovascular benefit of cholesterol-lowering therapy: does improved endothelial vasodilator function matter? , 2000, Circulation.

[18]  A. Skene,et al.  Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. , 2000, Circulation.

[19]  J. W. Box,et al.  Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators. , 2000, European heart journal.

[20]  P. Ridker,et al.  Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. , 1999, The American journal of cardiology.

[21]  E. Antman,et al.  Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. , 1999, Circulation.

[22]  KlasMalmberg,et al.  Glycometabolic State at Admission: Important Risk Marker of Mortality in Conventionally Treated Patients With Diabetes Mellitus and Acute Myocardial Infarction , 1999 .

[23]  Paul J Thornalley.  Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. , 1998, Cellular and molecular biology.

[24]  Hiroshi Yamamoto,et al.  Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells , 1998, Diabetologia.

[25]  G. Shen,et al.  Influence of glycation on LDL-induced generation of fibrinolytic regulators in vascular endothelial cells. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[26]  E. Antman,et al.  C-Reactive Protein Is a Potent Predictor of Mortality Independently of and in Combination With Troponin T in Acute Coronary Syndromes: A TIMI 11A Substudy , 1998 .

[27]  G. Remuzzi,et al.  Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. , 1998, The Journal of clinical investigation.

[28]  E. Antman,et al.  C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. , 1998, Journal of the American College of Cardiology.

[29]  F. Numano,et al.  The Effect of Glucose and Advanced Glycosylation End Products on IL‐6 Production by Human Monocytes , 1994, Annals of the New York Academy of Sciences.

[30]  S. Cobbe.  Thrombolysis in myocardial infarction , 1994, BMJ.